Fabian Lugo, MD
Neurology · Lafayette, LANPI 1538190798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 1,467 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,467 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Neurocrine Biosciences, Inc.$2K
- UCB, Inc.$2K
- Acadia Pharmaceuticals Inc$2K
- Biogen$1K
- Eisai Inc.$1K
- plus $14K from 51 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$26,21899%
- Education$2841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,517 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 48 | $229,858 |
| RytaryCarbidopa/Levodopa | 70 | $74,772 |
| Lamictal XrLamotrigine | 14 | $60,130 |
| Nurtec OdtRimegepant Sulfate | 48 | $59,030 |
| XcopriCenobamate | 48 | $58,333 |
| Austedo XrDeutetrabenazine | 12 | $57,631 |
| GocovriAmantadine Hcl | 13 | $40,466 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $36,288 |
| VimpatLacosamide | 13 | $34,098 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $31,845 |
| Emgality PenGalcanezumab-Gnlm | 37 | $25,492 |
| QuliptaAtogepant | 23 | $25,076 |
| BriviactBrivaracetam | 14 | $23,748 |
| UbrelvyUbrogepant | 20 | $21,660 |
| Rasagiline Mesylate | 82 | $15,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,631 | $229,85848 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $858 | $76,82197 claims |
| PfizerNurtec Odt, Lyrica | $610 | $67,54464 claims |
| SK Life Science, Inc.Xcopri | $1,099 | $58,33348 claims |
| UCB, Inc.Vimpat, Briviact | $1,870 | $57,84627 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $862 | $57,63112 claims |
| AbbVieQulipta, Ubrelvy | $3,716 | $46,73643 claims |
| MDD US Operations, LLCGocovri | $545 | $40,46613 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $248 | $31,84522 claims |
| Eisai Inc.Fycompa | $1,210 | $12,57412 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $167 | $11,84812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $6,28113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 neurology providers in Louisiana.
Other neurology in Lafayette
- Kevin HargraveLafayette$21K
- Virginia KellnerLafayette$18K
- Sahil ThankiLafayette$18K
- Steven SnaticLafayette$15K
- Thomas PrivettLafayette$15K
- Adam ForemanLafayette$12K
- Jonathan JonesLafayette$12K
- Wael AlabdulkarimLafayette$11K
- Tiffany LiuLafayette$10K
- Meghan HarrisShreveport$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.